

Date: 2nd July 2026
Ref: CORP 26/27 – 029

Dear xxx

Freedom of Information request: Treatment of Breast Cancer (CORP 26/27 – 029)

Thank you for your request for information which the Trust received on 3rd June 2026.

Your Request:

1. *How many patients have been treated for breast cancer (any stage) in the past 3 months with the following systemic anti-cancer therapies:*
 - *Abemaciclib + Aromatase Inhibitor (e.g. anastrozole, exemestane, letrozole)*
 - *Abemaciclib + Fulvestrant*
 - *Alpelisib + Fulvestrant*
 - *Anthracycline (e.g. doxorubicin or epirubicin) + Cyclophosphamide only*
 - *Anthracycline (e.g. doxorubicin or epirubicin) + Cyclophosphamide + Paclitaxel*
 - *Atezolizumab*
 - *Capivasertib*
 - *Capecitabine as a single agent*
 - *Carboplatin + Paclitaxel*
 - *Elacestrant*
 - *Eribulin as a single agent or in combination*
 - *Everolimus + Exemestane*
 - *Fulvestrant as a single agent*
 - *Palbociclib + Aromatase Inhibitor (e.g. anastrozole, exemestane, letrozole)*
 - *Palbociclib + Fulvestrant*
 - *Parp Inhibitors (Olaparib/Talazoparib)*
 - *Pembrolizumab Monotherapy*
 - *Pembrolizumab + Anthracycline (e.g. doxorubicin or epirubicin) + Cyclophosphamide*
 - *Carboplatin + Paclitaxel + Pembrolizumab*
 - *Pertuzumab (Perjeta) + Trastuzumab (Herceptin)*
 - *Phesgo (Pertuzumab + Trastuzumab in a single injection)*
 - *Ribociclib + Aromatase Inhibitor (e.g. anastrozole, exemestane, letrozole)*
 - *Ribociclib + Fulvestrant*
 - *Sacituzumab Govitecan*
 - *Taxane (e.g. docetaxel, paclitaxel, nab-paclitaxel) as a single agent*
 - *Trastuzumab deruxtecan (Enhertu)*
 - *Trastuzumab (Herceptin) as a single agent or in combination with Paclitaxel*
 - *Trastuzumab emtansine (Kadcyla)*
 - *Any other active systemic anti-cancer therapy*
 - *Pembrolizumab subcutaneous injection*

Mae Ymddiriedolaeth GIG Prifysgol Felindre yn hapus i dderbyn gohebiaeth yn y Gymraeg neu'r Saesneg.
Velindre University NHS Trust is happy to receive communication in Welsh or English.



- **Trastuzumab (Herceptin) as a single agent or in combination with Paclitaxel**
- **Trastuzumab emtansine (Kadcyla)**
- **Any other active systemic anti-cancer therapy**
- **Pembrolizumab subcutaneous injection**

There have been 1001 patients treated with the above systemic anti-cancer therapies. This is the number of unique patients treated with the above, some may have received more than one of drugs/treatments.

2. Does your trust participate in any clinical trials for breast cancer? If so, please provide the name of each trial, and the number of patients taking part.

Please see Appendix 1 below.

I trust this answers your request for information, however, should you not be satisfied with the information supplied or the process of supplying it, you have a right to complain and request a review. Please note that you must submit a request for a review within 40 days of the date of this letter.

You should forward your complaint to:


Mr Ian Bevan via FOI.VUNHST@wales.nhs.uk
Head of Information Governance
Velindre University NHS Trust
2, Charnwood Court
Heol Billingsley
Parc Nantgarw
Cardiff
CF15 7QZ

Should you wish to take your complaint further, if you are still unhappy with the decision after review, you can contact the:

Information Commissioner's Office - Wales
2nd Floor,
Churchill House,
Churchill Way,
Cardiff,
CF10 2HH
Telephone: 0330 414 6421
email: wales@ico.org.uk

Mae Ymddiriedolaeth GIG Prifysgol Felindre yn hapus i dderbyn gohebiaeth yn y Gymraeg neu'r Saesneg.
Velindre University NHS Trust is happy to receive communication in Welsh or English.





Appendix 1

No.	Acronym	IRAS ID	Full Title	Phase	Number recruited at Velindre
1	Phoenix	249774	A pre-surgical window of opportunity and post-surgical adjuvant biomarker study of DNA damage response inhibition and/or anti-PD-L1 immunotherapy in patients with neoadjuvant chemotherapy resistant residual triple negative breast cancer Version: 1.0	II/IIa	<6*
2	TROPION 05	1007219	D7630C00001 - A Phase III, Open-label, Randomised Study of Datopotamab Deruxtecan (Dato-DXd) in Combination with Durvalumab Compared with Investigator's Choice of Chemotherapy (Paclitaxel, Nab Paclitaxel or Gemcitabine + Carboplatin) in Combination with Pembrolizumab in Patients with PD L1 Positive Locally Recurrent Inoperable or Metastatic Triple Negative Breast Cancer	III	<6*
3	CELC-G-301 (A.K.A VIKTORIA 1)	1006613	A Phase 3, Open-Label, Randomized, Two-Part Study Comparing Gedatolisib in Combination with Palbociclib and Fulvestrant to Standard-of-Care Therapies in Patients with HR-Positive, HER2-Negative Advanced Breast Cancer Previously Treated with a CDK4/6 Inhibitor in Combination with Non-Steroidal Aromatase Inhibitor Therapy	III	6
4	TRAK-ER	286505	A randomised trial of early detection of molecular relapse with circulating tumour DNA tracking and treatment with palbociclib plus fulvestrant versus standard endocrine therapy in patients with ER positive HER2 negative breast cancer	II/IIa	28
5	CAMBRIA-2	1007986	A Phase III, Open-Label, Randomised Study to Assess the Efficacy and Safety of Camizestrant (AZD9833, a Next Generation, Oral Selective Estrogen Receptor Degradar) Versus Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) as Adjuvant Treatment for Patients with ER+/HER2- Early Breast Cancer and an Intermediate-High or High Risk of Recurrence Who Have Completed Definitive Locoregional Treatment and Have No Evidence of Disease	III	8
6	MOLGEN	7086	MOLECULAR GENETICS OF ADVERSE DRUG REACTIONS - MOLGEN	N/A	<6*
7	DYNASTY-Breast02	1009062	A Phase 3, Randomized, Multi-center, Open-label Study of DB-1303 Versus Investigator's Choice Chemotherapy in Human Epidermal Growth Factor Receptor 2 (HER2)-low, Hormone Receptor Positive (HR+) Metastatic Breast Cancer Patients whose Disease has Progressed on Endocrine Therapy (ET)	III	<6*
8	HER2-RADiCAL	292122	(Response ADaptive CAre pLan) – Tailoring treatment for HER2 positive early breast cancer	III	<6*
9	BNT323-03	1011776	Phase I/II, multi-site, open-label, two-part trial to evaluate the efficacy, safety, and pharmacokinetics of BNT323 in combination with BNT327 in participants with advanced breast cancer	I/Ib	0
10	HER2+ CNS Surveillance study	341272	A Study of the feasibility of randomising women and men with HER2 Positive metastatic breast cancer to Central Nervous System surveillance versus no surveillance	N/A	6
11	MK2870-011-4008 (TROFUSE 11)	1010956	A Phase 3, Randomised, Open-label Study Comparing Efficacy and Safety of Sacituzumab Tirumotecan (sac-TMT, MK-2870) as a Monotherapy and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With Previously Untreated Locally Recurrent Unresectable or Metastatic Triple-Negative Breast Cancer Expressing PD L1 at CPS Less than 10	III	<6*

Appendix 1

12	Beamion BCGC-1	1011679	A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC)	I/Ib	0
13	ASPEN-09-03	1012669	A Single-arm Phase 2 Multicenter Study of Evorpaccept in Combination with Trastuzumab and Chemotherapy in Participants with Metastatic HER2-Positive Breast Cancer (ASPEN-09-03)	II/IIa	<6*
14	OPTIMA	95626	Optimal Personalised Treatment of early breast cancer using Multi-parameter Analysis	III	166
15	OLYMPIA	145475	A randomised, double-blind, parallel group, placebo-controlled multi-centre Phase III study to assess the efficacy and safety of olaparib versus placebo as adjuvant treatment in patients with germline BRCA1/2 mutations and high risk HER2 negative primary breast cancer who have completed definitive local treatment and neoadjuvant or adjuvant chemotherapy	III	8
16	PALLAS	200813	PALbociclib CoLaborative Adjuvant Study	III	22
17	PARTNER	178681	Randomised, phase II/III, 3 stage trial to evaluate the safety and efficacy of the addition of olaparib to platinum-based neoadjuvant chemotherapy in breast cancer patients with TNBC and/or gBRCA.	III	40
18	SPECTA	223041	Screening Cancer Patients for Efficient Clinical Trial Access	N/A	19
19	NATALEE / TRIO033	255897	A phase III, multicenter, randomized, open-label trial to evaluate efficacy and safety of ribociclib with endocrine therapy as an adjuvant treatment in patients with hormone receptor-positive, HER2-negative, early breast cancer (New Adjuvant TriAl with Ribociclib [LEE011]:NATALEE).	III	9
20	BPRE15E 01 (B-precise-01)	242689	OPEN-LABEL, MULTICENTRE, PHASE IB DOSE-ESCALATION STUDY OF MEM611, A P13K INHIBITOR COMBINED WITH TRASTUZUMAB ± FULVESTRANT, IN SUBJECTS WITH PIK3CA MUTATED HER2-POSITIVE LOCALLY RECURRENT UNRESECTABLE (ADVANCED) OR METASTATIC (A/M) BREAST CANCER PROGRESSED TO ANTI-HER2 BASED THERAPY	I/Ib	<6*
21	CAPItello - 291	275926	A Phase III Double-blind Randomised Study Assessing the Efficacy and Safety of Capivasertib + Fulvestrant Versus Placebo + Fulvestrant as Treatment for Locally Advanced (Inoperable) or Metastatic Hormone Receptor Positive, Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Breast Cancer Following Recurrence or Progression On or After Treatment with an Aromatase Inhibitor (CAPItello-291)	III	9
22	D9670C00001 (DESTINY-Breast06)	1003048	A Phase 3, Randomized, Multi-center, Open-label Study of Trastuzumab Deruxtecan (T-DXd) Versus Investigator's Choice Chemotherapy in HER2-low, Hormone Receptor Positive Breast Cancer Patients whose Disease has Progressed on Endocrine Therapy in the Metastatic Setting	III	<6*
23	TROPION 02	1005082	A Phase 3, Open-label, Randomised Study of Datopotamab Deruxtecan (Dato-DXd) Versus Investigator's Choice of Chemotherapy in Patients who are not Candidates for PD-1/PD-L1 Inhibitor Therapy in First-line Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer	III	<6*

Appendix 1

24	TROPION 03	1006335	A Phase 3 Open-label, Randomised Study of Datopotamab Deruxtecan (Dato-DXd) With or Without Durvalumab Versus Investigator's Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Who Have Residual Invasive Disease in the Breast and/or Axillary Lymph Nodes at Surgical Resection Following Neoadjuvant Systemic Therapy	III	11
25	TROPION 04	1008502	Phase III, Open-label, Randomised Study of Neoadjuvant Datopotamab Deruxtecan (Dato-DXd) Plus Durvalumab Followed by Adjuvant Durvalumab With or Without Chemotherapy Versus Neoadjuvant Pembrolizumab Plus Chemotherapy Followed by Adjuvant Pembrolizumab With or Without Chemotherapy for the Treatment of Adult Patients With Previously Untreated Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer	III	<6*
26	PARABLE	302709	Proton beam therapy in patients with breast cancer: Evaluating early and late effects	N/A	<6*
27	FAIM	284870	Randomised Open-label Phase II study of induction standard of care Fulvestrant and CDK4/6 inhibition with the Addition of Ipatasertib in Metastatic ER+/HER2- breast cancer patients without ctDNA suppression	II/IIa	<6*

* Where the figure provided is less than 6, and where simple calculations could identify fields that contain less than 6, the Trust has applied an exemption under Section 40(2) (personal data) of the Freedom of Information Act 2000. This is because the Trust believes there is a potential risk of individuals being able to be identified if the figures were disclosed.